CN1569219A - Eye drop for treating amblyopia and its preparing process - Google Patents
Eye drop for treating amblyopia and its preparing process Download PDFInfo
- Publication number
- CN1569219A CN1569219A CN 03126251 CN03126251A CN1569219A CN 1569219 A CN1569219 A CN 1569219A CN 03126251 CN03126251 CN 03126251 CN 03126251 A CN03126251 A CN 03126251A CN 1569219 A CN1569219 A CN 1569219A
- Authority
- CN
- China
- Prior art keywords
- eye drop
- levodopa
- grams
- add
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a Levodopa, dermatan sulfate and mentha camphor containing eye drop to treat amblyopia. The prescription of the eye drop is Levodopa 5-50g, dermatan sulfate 10-50g, mentha camphor 10-50 mg in per 1000 ml eye drop. PH is controlled between 5.5-7.0, osmotic pressure ranges between 250-350mOsm.
Description
The present invention relates to a kind of levodopa (Levodopa), dermatan sulfate (dermatan sulfate) and menthol of comprising, be used for the treatment of amblyopia.
Eye drop of the present invention generally by aseptic subpackaged in the medical eye drops bottle of 8～10ml; Each 1～2 splashes in the eye during use, can be interrupted every day and use 1～6 time.
The prescription of eye drop of the present invention is: contain levodopa 5～50 grams in every 1000ml eye drop, sulfur acid dermatan 10～50 grams contain 10～50 milligrams of menthols.
Eye drop of the present invention also can add necessary pH regulator agent (as citric acid-sodium citrate, dilute hydrochloric acid, sodium hydroxide, sodium borate and sodium bicarbonate) to keep pH 5.5～8.0.
Eye drop of the present invention also can add necessary antiseptic (as Buddhist nun uncle tortoise beetle ester, Ethyl Hydroxybenzoate, boric acid etc.).
The present invention also can add glucose or sodium chloride, to keep osmotic pressure at 250～350mOsm.
Except that above-mentioned main component, the present invention also can add the various components that are suitable for ordinary eye drops or other effective ingredient (improving the medicine of therapeutic effect of the present invention as buffer agent, isotonic agent, bulking agent, viscosifier, chelating agen, stabilizing agent and other) when needed, and how the use of these components is can not be to the degree that lowers or influence effect of the present invention.
The levodopa that the present invention uses is recorded by the Pharmacopoeia of the People's Republic of China 2000 editions as medicine, is safe when using in range of doses.Be in the news the oral child of being used for the treatment of and adult's amblyopia of levodopa is effectively, and also is safe when using in range of doses; But because oral dose is relatively large, still some side effect can take place, as feel sick, vomiting, gastrointestinal upset, dizziness, slight drowsiness etc.And levodopa is when using as eye liquid, and its consumption only is equivalent to 1/10～1/3 of whole body consumption, does not observe the side effect of levodopa.
Because levodopa is a kind of organic weak base class medicine, the levodopa that the present invention uses is its soluble-salt (example hydrochloric acid salt, a sulfate etc.).
The dermatan sulfate that the present invention uses is a micromolecule native protein polysaccharide, mainly be present in human and tissues such as other mammalian skin, ligament, cartilage in, have tackify, lubricate, preserve moisture, the anti-ageing effect of waiting for a long time.
The menthol that the present invention uses can make the local refrigerant comfortable sensation that produces.
Embodiment 1
Hydrochloric acid levodopa (medicinal) 25 grams, dermatan sulfate 25 grams, 25 milligrams of menthols (medicinal), boric acid 14 grams, Borax 3 grams, 50 milligrams of phenylmercuric nitrate add water for injection 50～100ml dissolving back respectively and mix, add pH regulator agent (10% dilute hydrochloric acid/sodium hydroxide), regulate pH 5.5～7.0, osmotic pressure should add the injection water to 1000ml, 0.22 μ m microporous filter membrane aseptic filtration at 250～350mOsm, be sub-packed in 8～10ml sterilization eye drops bottle, seal.
Embodiment 2
Hydrochloric acid levodopa (medicinal) 30 grams, dermatan sulfate 50 grams, boric acid 18 grams, Borax 1 gram, 100 milligrams of thimerosal, 50 milligrams of menthols (medicinal) add water for injection 50～100ml dissolving back respectively and mix, add pH regulator agent (10% dilute hydrochloric acid/sodium hydroxide), regulate pH 5.5～7.0, osmotic pressure should add the injection water to 1000ml, 0.22 μ m microporous filter membrane aseptic filtration at 250～350mOsm, be sub-packed in 8～10ml sterilization eye drops bottle, seal.
Embodiment 3
Hydrochloric acid levodopa (medicinal) 30 grams, dermatan sulfate 50 grams, boric acid 18 grams, Borax 0.1 gram, 20 milligrams of benzyl chloride alkanamines, 50 milligrams of menthols (medicinal) add water for injection 50～100ml dissolving back respectively and mix, add pH regulator agent (10% dilute hydrochloric acid/sodium hydroxide), regulate pH 5.5～7.0, osmotic pressure should add the injection water to 1000ml, 0.22 μ m microporous filter membrane aseptic filtration at 250～350mOsm, be sub-packed in 8～10ml sterilization eye drops bottle, seal.
Claims (3)
1. eye drop, feature is that main component is levodopa (Levodopa), dermatan sulfate and menthol, is used for the treatment of amblyopia.
2. press claims 1 described eye drop, add necessary osmotic pressure regulator, pH buffer system and antiseptic etc. during its feature also is to fill a prescription.
3. press claims 1 described eye drop, the levodopa during its feature also is to fill a prescription is its soluble-salt (example hydrochloric acid salt, a sulfate etc.).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03126251 CN1569219A (en) | 2003-07-14 | 2003-07-14 | Eye drop for treating amblyopia and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03126251 CN1569219A (en) | 2003-07-14 | 2003-07-14 | Eye drop for treating amblyopia and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1569219A true CN1569219A (en) | 2005-01-26 |
Family
ID=34469071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03126251 Pending CN1569219A (en) | 2003-07-14 | 2003-07-14 | Eye drop for treating amblyopia and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1569219A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180140561A1 (en) * | 2007-06-29 | 2018-05-24 | Phovitreal Pty Ltd | Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration |
| CN109310658A (en) * | 2016-04-11 | 2019-02-05 | 堪培拉大学 | Ophthalmic composition comprising levodopa, antioxidant and aqueous carrier |
-
2003
- 2003-07-14 CN CN 03126251 patent/CN1569219A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180140561A1 (en) * | 2007-06-29 | 2018-05-24 | Phovitreal Pty Ltd | Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration |
| US12042471B2 (en) * | 2007-06-29 | 2024-07-23 | Photopharmics, Inc. | Ocular treatments for neurological and neuropsychiatric disorders |
| CN109310658A (en) * | 2016-04-11 | 2019-02-05 | 堪培拉大学 | Ophthalmic composition comprising levodopa, antioxidant and aqueous carrier |
| EP3442516A4 (en) * | 2016-04-11 | 2019-12-18 | University of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| US11890266B2 (en) | 2016-04-11 | 2024-02-06 | University Of Canberra | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10413563B2 (en) | Neurochemical wellness program | |
| CN101278908A (en) | Eye drop capable of significantly increasing medicament effect | |
| CN1569219A (en) | Eye drop for treating amblyopia and its preparing process | |
| RU2086237C1 (en) | Agent for alcoholic abstinent syndrome arresting | |
| RU2706712C1 (en) | Drops for children | |
| RU2739192C1 (en) | Method of treating abstinence syndrome, in order to prevent developing psychosis, in individuals with dependence on synthetic agonists of gamma-aminobutyric acid receptors: butyrolactone, 1,4-butanediol | |
| RU2196590C1 (en) | Agent carbon-mercury hydrosulfate complex and method of treatment of infectious inflammatory sicknesses | |
| Shreeve | Alternative Dictionary Of Symptoms And Cures: A Comprehensive Guide to Diseases and Their Orthodox and Alternative Remedies | |
| CN1261106C (en) | Externally applied liquor for treating psoriasis | |
| RU2200561C1 (en) | Method for treating and preventing diseases | |
| CN1128656A (en) | Application of anisodamine for prepn. of eye drops for curing pyopia | |
| CN115105468A (en) | Dibazol eye drops and preparation method thereof | |
| CN1628695A (en) | Eye lotion containing hyaluronic acid and hyaluronic salt and method for making same | |
| CN112354051A (en) | Eye-protecting medicament fumigating volatilizer | |
| Burić | THE NURSE'S ROLE IN PREPARING THE INFUSION FOR REJUVENATING AND BOOSTING THE PATIENT'S IMMUNITY. | |
| TW321603B (en) | Pharmaceutical composition for treating drug addicts' withdrawal syndromes and detoxifying addicts by the same | |
| Winters et al. | Prolonged coma caused by glutethimide | |
| RU2083231C1 (en) | Method for body detoxication | |
| CN1554347A (en) | Therapeutic liquid for treating leuconychia | |
| Diggs | Laughter: Is it Healthy | |
| RU2211060C2 (en) | Method for treating acute period of hypothalamic syndrome in pubertal period | |
| SALTS | THE COMPOSITION OF CERTAIN SECRET REMEDIES. | |
| RU2495670C2 (en) | Method for addictive behaviour correction | |
| CN1110306C (en) | High effect mycin powder injection | |
| UA144746U (en) | METHOD OF PREVENTION AND TREATMENT OF DISEASES CAUSED BY VIRUSES, INCLUDING CORONAVIRUSES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |